Oncology Clinical Trial:
Our dedication to patient well-being has already fueled progress, but the complexities of cancer demand cutting-edge solutions. We remain focused on enhancing clinical outcomes and providing long-term treatment options to address these challenges in oncology.
By pushing the boundaries of cancer care, we aim to revolutionize oncology treatment, alleviating the burden on patients and their families. Together, we envision a future where cancer is better understood, and lives are transformed through breakthrough clinical research and therapies.
- Breast Cancer
- Lung Cancer
- Biliary Tract Cancer
- Gastric Cancer
- Liver Cancer
- Head and Neck
- Gynecological Cancer
- Hematological Cancer
Breast Cancer Studies:
1L TNBC: TROPION BREAST05
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
1L BRCA1, BRCA2 or PALB2m (EvoPAR-Breast01)
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant compared with Physician’s Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients with BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
Any Questions?
If you have any questions about AZ clinical trials, please contact us!
TH-20822 EXP: 16/10/2026
Lung Cancer Studies:
Adj EGFR+ (TROPION LUNG12)
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12)
PD-L1 >1: PACIFIC-8
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab(AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy
1L HER2+: Destiny Lung03
A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents with and Without Chemotherapy Agents in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)
1L PD-L1 negative/low: eVOLVE-Lung02
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC).
Sq PD-L1 low/high: Artemide Lung02
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)
NSQ PD-L1 high (TROPION LUNG10)
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)
2L+ Sq B7H4+: BLUESTAR
A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Solid Tumors (BLUESTAR)
Any Questions?
If you have any questions about AZ clinical trials, please contact us!
TH-20822 EXP: 16/10/2026
Biliary Tract Cancer Studies:
1L HER2 (IHC 3+) (DESTINY BTC01)
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer
1L BTC (ARTEMIDE BTC02)
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) - AB02
Any Questions?
If you have any questions about AZ clinical trials, please contact us!
TH-20822 EXP: 16/10/2026
Gastric Cancer Studies:
2L+ HER2-neg/low: Clarity Gastric01
A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
1L HER2+: ARTEMIDE-GASTRIC01
A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)
Any Questions?
If you have any questions about AZ clinical trials, please contact us!
TH-20822 EXP: 16/10/2026
Liver Cancer Studies:
1L HCC (ARTEMIDE HCC01)
Phase III Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma - ARTEMIDE-HCC01
Any Questions?
If you have any questions about AZ clinical trials, please contact us!
TH-20822 EXP: 16/10/2026
Head and Neck Cancer Studies:
eVOLVE-HNSCC
A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)
Any Questions?
If you have any questions about AZ clinical trials, please contact us!
TH-20822 EXP: 16/10/2026
Gynecological Cancer Studies:
Consolidation post CCRT LACC: eVOVLE-Cervical
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)
Any Questions?
If you have any questions about AZ clinical trials, please contact us!
TH-20822 EXP: 16/10/2026
Hematological Cancer Studies:
1L FL: SOUNDTRACK-F1
A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma (SOUNDTRACK-F1)
Any Questions?
If you have any questions about AZ clinical trials, please contact us!
TH-20822 EXP: 16/10/2026
Breast Cancer Studies:
1L TNBC: TROPION BREAST05
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
1L BRCA1, BRCA2 or PALB2m (EvoPAR-Breast01)
A Randomised, Open-Label, Phase III Study of Saruparib (AZD5305) Plus Camizestrant compared with Physician’s Choice CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant for the First-Line Treatment of Patients with BRCA1, BRCA2, or PALB2 Mutations and Hormone Receptor Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified) Advanced Breast Cancer (EvoPAR-Breast01)
Any Questions?
If you have any questions about AZ clinical trials, please contact us!
TH-20822 EXP: 16/10/2026
Lung Cancer Studies:
Adj EGFR+ (TROPION LUNG12)
A Phase III, Randomised, Open-label, Global Study of Adjuvant Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma Non-small Cell Lung Cancer who are ctDNA-positive or Have High-risk Pathological Features (TROPION-Lung12)
PD-L1 >1: PACIFIC-8
A Phase III, Randomised, Double-blind, Placebo-controlled, Multicentre, International Study of Durvalumab plus Domvanalimab(AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum-based Concurrent Chemoradiation Therapy
1L HER2+: Destiny Lung03
A Phase Ib Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Immunotherapy Agents with and Without Chemotherapy Agents in First-line Treatment of Patients with Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 (HER2) Overexpression (OE) (DESTINY-Lung03)
1L PD-L1 negative/low: eVOLVE-Lung02
A Phase III, Two-Arm, Parallel, Randomized, Multi-Center, Open-Label, Global Study to Determine the Efficacy of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer (mNSCLC).
Sq PD-L1 low/high: Artemide Lung02
A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)
NSQ PD-L1 high (TROPION LUNG10)
A Phase III, Randomised, Open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination with Rilvegostomig or Rilvegostomig Monotherapy Versus Pembrolizumab Monotherapy for the First-line Treatment of Participants With Locally-advanced or Metastatic Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations (TROPION-Lung10)
2L+ Sq B7H4+: BLUESTAR
A Phase I/IIa Multi-center, Open-label Master Protocol Dose Escalation and Expansion Study of AZD8205 as Monotherapy and in Combination with Anticancer Agents in Participants with Advanced Solid Tumors (BLUESTAR)
Any Questions?
If you have any questions about AZ clinical trials, please contact us!
TH-20822 EXP: 16/10/2026
Biliary Tract Cancer Studies:
1L HER2 (IHC 3+) (DESTINY BTC01)
DESTINY-Biliary Tract Cancer-01: A Phase 3 Study of Trastuzumab Deruxtecan (T-DXd) and Rilvegostomig versus Standard-of-Care Gemcitabine, Cisplatin, and Durvalumab for First Line Locally Advanced or Metastatic HER2-expressing Biliary Tract Cancer
1L BTC (ARTEMIDE BTC02)
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) - AB02
Any Questions?
If you have any questions about AZ clinical trials, please contact us!
TH-20822 EXP: 16/10/2026
Gastric Cancer Studies:
2L+ HER2-neg/low: Clarity Gastric01
A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared with Investigator’s Choice of Therapy in Second- or Later-Line Adult Participants with Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
1L HER2+: ARTEMIDE-GASTRIC01
A Randomized, Phase Ⅲ Study of Rilvegostomig in Combination with Fluoropyrimidine and Trastuzumab Deruxtecan versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First line Treatment of HER2-positive Gastric Cancer (ARTEMIDE-Gastric01)
Any Questions?
If you have any questions about AZ clinical trials, please contact us!
TH-20822 EXP: 16/10/2026
Liver Cancer Studies:
1L HCC (ARTEMIDE HCC01)
Phase III Study of Rilvegostomig in Combination with Bevacizumab with or without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma - ARTEMIDE-HCC01
Any Questions?
If you have any questions about AZ clinical trials, please contact us!
TH-20822 EXP: 16/10/2026
Head and Neck Cancer Studies:
eVOLVE-HNSCC
A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)
Any Questions?
If you have any questions about AZ clinical trials, please contact us!
TH-20822 EXP: 16/10/2026
Gynecological Cancer Studies:
Consolidation post CCRT LACC: eVOVLE-Cervical
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum-based, Concurrent Chemoradiation Therapy (eVOLVE-Cervical)
Any Questions?
If you have any questions about AZ clinical trials, please contact us!
TH-20822 EXP: 16/10/2026
Hematological Cancer Studies:
1L FL: SOUNDTRACK-F1
A Phase III, Multicentre, Randomised, Open-label Study to Compare the Efficacy and Safety of AZD0486 plus Rituximab versus Chemotherapy plus Rituximab in Previously Untreated Participants with Follicular Lymphoma (SOUNDTRACK-F1)
Any Questions?
If you have any questions about AZ clinical trials, please contact us!
TH-20822 EXP: 16/10/2026
Thank you for your interest in our clinical research. In order to provide you with tailored information and support, we kindly request the following details:
By providing us with this information, we will ensure that our response is focused on your area of interest and can be delivered in a manner that is most convenient for you.
We appreciate your interest and look forward to the opportunity to assist you further.
onco-tab1
onco-tab2
onco-tab3
onco-tab4
onco-tab5
onco-tab6
onco-tab7
oncotab-8
This website is intended for Healthcare Professionals in Thailand.
TH-28626
© AstraZeneca 2026
Our policies
Information
Contact Us
AstraZeneca (Thailand) Ltd.
Asia Centre Building, 19th Floor,
173/20 South Sathorn Road, Thungmahamek,
Sathorn, Bangkok, 10120, Thailand.
Tel: +66 (2) 739 7400, Fax: +66 (2) 739 7497